Covance Receives MHRA Accreditation for UK Facility
July 30, 2009, Princeton, NJ
The Medicines and Healthcare products Regulatory Agency (MHRA) awarded Covance's (Princeton, NJ) clinical research unit in Leeds, UK, where the company conducts first-in-human studies, with standard and supplementary accreditation for the conduct of clinical pharmacology in Europe. The MHRA accreditation, which is voluntary, ensures that research facilities and studies meet industry standards for patient safety in early clinical development.
"Covance delivers the highest level of data quality and safety for first-in-human trials, which is confirmed by the accreditation," said Rob Aspbury, MD, Covance's managing director of clinical research services, in a press release.
In order to receive this type of accreditation, formal inspections are performed by MHRA, which is based in London.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
